



Contact:  
David Waldman or Justyna Gudaszevska  
Crescendo Communications, LLC  
Email: [mmd@crescendo-ir.com](mailto:mmd@crescendo-ir.com)  
Tel: +48 693 354 580

**International Multicenter Study Finds Milestone Medical's CompuFlo® Epidural System Safe Alternative to Traditional Epidural Method**

*No accidental dural punctures reported using the CompuFlo® Epidural System*

*Poster Presented at ANESTHESIOLOGY® 2019 Annual Meeting*

**LIVINGSTON, NJ, October 21, 2019 – Milestone Medical Inc. (WAR: MMD)** today reported the results of an international multicenter study that compared the accidental dural puncture rate and its complications while using the CompuFlo® Epidural System versus traditional loss of resistance technique in patients under labor epidural analgesia.

This is the first international multicenter study to compare the incidence of accidental dural puncture using the CompuFlo® Epidural System versus the continuous loss of resistance (LOR) technique. The study collected records between 2015 and 2019 of epidural administration on labor and delivery patients using the CompuFlo® Epidural System from four institutions, one in the U.S., one in Chile, and two from Italy. Among the four sites, there were 812 patients who received epidural analgesia with CompuFlo® and none had accidental dural puncture regardless of the composition of the epidural performer types. In comparison, the rate of accidental dural puncture was 5% in the LOR group in the non inferiority trial<sup>1</sup>.

The Company also announced that Professor Rovnat Babazade, MD, University of Texas Medical Branch at Galveston, Department of Anesthesiology, presented a poster at the ANESTHESIOLOGY® 2019 Annual Meeting in Orlando, Florida on Monday, October 21, 2019. The poster, entitled, "International Multicenter Study of Accidental Dural Puncture Rate; Comparison of the CompuFlo with Traditional Method," is available online at: [LINK]. ANESTHESIOLOGY 2019, hosted by the American Society of Anesthesiologists (ASA), unites more than 14,000 clinicians, thought leaders and professionals from around the world.

---

<sup>1</sup> Gebhard RE. Objective epidural space identification using continuous real time pressure sensing technology: a randomized controlled comparison with fluoroscopy and traditional loss of resistance. *Anesthesia & Analgesia*. 2018

Leonard Osser, Chief Executive Officer of Milestone Medical, commented, “This study is another validation that the CompuFlo epidural instrument is a safe, proven alternative to the loss of resistance technique being used by most medical professionals. Loss of resistance is subjective and consequently associated with failure rates and accidental dural punctures that require further treatment and interventions such as epidural blood patches. The fact that none of the 812 patients who received epidural analgesia with CompuFlo® had an accidental dural puncture is a testament that our technology is effective in accurately identifying the epidural space. We are honored to have the results of this trial presented by Professor Rovnat Babazade at ANESTHESIOLOGY 2019 in front of world leaders in the field of anesthesia.”

**About Milestone Medical Inc.**

Milestone Medical, Inc. has developed epidural and intra-articular drug delivery systems based on a patented, painless, computer-controlled injection and drug delivery technology originally developed by Milestone Scientific, Inc. Development of both the epidural and intra-articular instruments is now complete. The Company was granted the FDA marketing clearance of the epidural instrument in U.S. and is currently pursuing regulatory approval for intra-articular instrument in the U.S. Milestone Medical received CE Mark approval to sell and market its intra-articular and epidural instruments across European Union. For more information please visit [www.medicalmilestone.com](http://www.medicalmilestone.com).

**Safe Harbor Statement**

*This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2018. The forward-looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.*